2022
Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression.
Comba A, Faisal SM, Dunn PJ, Argento AE, Hollon TC, Al-Holou WN, Varela ML, Zamler DB, Quass GL, Apostolides PF, Abel C 2nd, Brown CE, Kish PE, Kahana A, Kleer CG, Motsch S, Castro MG, Lowenstein PR.
Nat Commun. 2022 Jun 24;13(1):3606.
doi: 10.1038/s41467-022-31340-1
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, Apfelbaum AA, Lawlor ER, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Sun Y, Gan J, Ackermann R, Schwendeman A, Candolfi M, Olin MR, Lahann J, Lowenstein PR, Castro MG.
ACS Nano. 2022 May 26.
doi: 10.1021/acsnano.1c07492
2021
Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications
Comba Andrea, Faisal Syed M., Varela Maria Luisa, Hollon Todd, Al-Holou Wajd N., Umemura Yoshie, Nunez Felipe J., Motsch Sebastien, Castro Maria G., Lowenstein Pedro R.
Front. Oncol., 05 Aug 2021
doi: 10.3389/fonc.2021.703764
A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1.
Shah D, Comba A, Faisal SM, Kadiyala P, Baker GJ, Alghamri MS, Doherty R, Zamler D, Nuñez G, Castro MG, Lowenstein PR.
Oncoimmunology. 2021 Jun 28;10(1):1939601.
doi: 10.1080/2162402X.2021.1939601
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Garcia-Fabiani MB, Haase S, Comba A, Carney S, McClellan B, Banerjee K, Alghamri MS, Syed F, Kadiyala P, Nunez FJ, Candolfi M, Asad A, Gonzalez N, Aikins ME, Schwendeman A, Moon JJ, Lowenstein PR, Castro MG.
Front Oncol. 2021 Jun 8;11:631037.
doi: 10.3389/fonc.2021.631037
2020
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB, Ventosa M, Comba A, Candolfi M, Nicola Candia AJ, Alghamri MS, Kadiyala P, Carney S, Faisal SM, Schwendeman A, Moon JJ, Scheetz L, Lahann J, Mauser A, Lowenstein PR, Castro MG.
Expert Opin Investig Drugs. 2020 Jul;29(7):659-684.
DOI: 10.1080/13543784.2020.1768528
Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses.
Comba A, Dunn PJ, Argento AE, Kadiyala P, Ventosa M, Patel P, Zamler DB, Núñez FJ, Zhao L, Castro MG, Lowenstein PR.
Neuro Oncol. 2020 Jun 9;22(6):806-818.
DOI: 10.1093/neuonc/noaa006
Erratum: Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses.
Comba A, Dunn PJ, Argento AE, Kadiyala P, Ventosa M, Patel P, Zamler DB, Nunez FJ, Zhao L, Castro MG, Lowenstein PR.
Neuro Oncol. 2020 May 19:noaa063.
DOI: 10.1093/neuonc/noaa063
Self-organization in brain tumors: How cell morphology and cell density influence glioma pattern formation.
Jamous S, Comba A, Lowenstein PR, Motsch S.
PLoS Comput Biol. 2020 May 7;16(5):e1007611.
DOI: 10.1371/journal.pcbi.1007611
Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion.
Comba A, Dunn PJ, Kish PE, Kadiyala P, Kahana A, Castro MG, Lowenstein PR.
J Vis Exp. 2020 Apr 12;(158):10.3791/60939.
DOI: 10.3791/60939
Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system.
Garcia-Fabiani MB, Comba A, Kadiyala P, Haase S, Núñez FJ, Altshuler D, Lowenstein PR, Castro MG.
Methods Enzymol. 2020;632:369-388.
DOI: 10.1016/bs.mie.2019.05.023
